Vildagliptin
From Wikipedia, the free encyclopedia
 |
|
|
Vildagliptin
|
|
| Systematic (IUPAC) name | |
| (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl] pyrrolidine-2-carbonitrile |
|
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | 6918537 |
| Chemical data | |
| Formula | C17H25N3O2 |
| Mol. weight | 303.399 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Vildagliptin, previously identified as LAF237, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
It is currently in clinical trials and has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[1]
Vildagliptin has been submitted to the U.S. Food and Drug Administration for approval, and will be marketed as Galvus® by Novartis.
Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP[2] and the degradation of GLP-1.[1][2]
[edit] See also
[edit] References
- ^ a b Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004 May;89(5):2078-84. PMID 15126524. Free Full Text.
- ^ a b Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. PMID 8100523.
[edit] External links
- Vildagliptin - glucagon.com
- About DPP-4 - glucagon.com
- The race to get DPP-4 inhibitors to market - Forbes.com
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
